Literature DB >> 11429705

p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.

P Campomenosi1, P Monti, A Aprile, A Abbondandolo, T Frebourg, B Gold, T Crook, A Inga, M A Resnick, R Iggo, G Fronza.   

Abstract

The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e.g. p21) or apoptosis (e.g. Bax, PIG3). Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription. Identification of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, Bax and PIG3 genes. We also assessed the influence of temperature on transactivation. Our results indicate that a significant proportion of mutants [16/77 (21%); 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially affect less conserved (P<0.04, Fisher's exact test), more rarely mutated (P<0.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P<0.003, Fisher's exact test). Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was significantly higher than in the panel of mutants studied previously (P<0.001, Fisher's exact test). Since it is not possible to predict the behaviour of a mutant from first principles, we propose that the yeast assay be used to compile a functional p53 database and fill the gap between the biophysical, pharmacological and clinical fields.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429705     DOI: 10.1038/sj.onc.1204468

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

1.  Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.

Authors:  Michael A Resnick; Alberto Inga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

2.  Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.

Authors:  Ricardo E Perez; Chad D Knights; Geetaram Sahu; Jason Catania; Vamsi K Kolukula; Daniel Stoler; Adolf Graessmann; Vasily Ogryzko; Michael Pishvaian; Christopher Albanese; Maria Laura Avantaggiati
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

3.  Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinone oxidoreductase PIG3.

Authors:  Sergio Porté; Eva Valencia; Evgenia A Yakovtseva; Emma Borràs; Naeem Shafqat; Judit E Debreczeny; Ashley C W Pike; Udo Oppermann; Jaume Farrés; Ignacio Fita; Xavier Parés
Journal:  J Biol Chem       Date:  2009-04-05       Impact factor: 5.157

4.  Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain.

Authors:  Ulrika Nyman; Pinelopi Vlachos; Anna Cascante; Ola Hermanson; Boris Zhivotovsky; Bertrand Joseph
Journal:  Mol Cell Biol       Date:  2009-01-21       Impact factor: 4.272

5.  Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis.

Authors:  Peter G Fuhrken; Pani A Apostolidis; Stephan Lindsey; William M Miller; Eleftherios T Papoutsakis
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

6.  Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.

Authors:  Paola Monti; Chiara Perfumo; Alessandra Bisio; Yari Ciribilli; Paola Menichini; Debora Russo; David M Umbach; Michael A Resnick; Alberto Inga; Gilberto Fronza
Journal:  Mol Cancer Res       Date:  2011-02-22       Impact factor: 5.852

7.  High frequency of temperature-sensitive mutants of p53 in glioblastoma.

Authors:  Jana Smardova; Kvetoslava Liskova; Barbora Ravcukova; Lenka Kubiczkova; Sabina Sevcikova; Jaroslav Michalek; Miluse Svitakova; Vaclav Vybihal; Leos Kren; Jan Smarda
Journal:  Pathol Oncol Res       Date:  2013-03-28       Impact factor: 3.201

8.  Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.

Authors:  Joshua Merritt; Kim G Roberts; James A Butz; Jeremy S Edwards
Journal:  Genomic Med       Date:  2007-09-05

9.  Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53.

Authors:  Guoqiang Ai; Rakesh Dachineni; D Ramesh Kumar; Srinivasan Marimuthu; Lloyd F Alfonso; G Jayarama Bhat
Journal:  Tumour Biol       Date:  2015-11-23

10.  Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.

Authors:  Uma Chandrachud; Susannah Gal
Journal:  Technol Cancer Res Treat       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.